Bokf Na increased its position in Teva Pharm Adr (NYSE:TEVA) by 2.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,868 shares of the company’s stock after buying an additional 521 shares during the period. Bokf Na’s holdings in Teva Pharm Adr were worth $1,052,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of TEVA. Stephens Inc. AR boosted its stake in shares of Teva Pharm Adr by 66.5% in the third quarter. Stephens Inc. AR now owns 15,520 shares of the company’s stock worth $714,000 after buying an additional 6,199 shares in the last quarter. First City Capital Management Inc. acquired a new stake in shares of Teva Pharm Adr during the third quarter worth about $549,000. BRYN MAWR TRUST Co boosted its stake in shares of Teva Pharm Adr by 2.6% in the third quarter. BRYN MAWR TRUST Co now owns 8,890 shares of the company’s stock worth $409,000 after buying an additional 225 shares in the last quarter. Chemical Bank boosted its stake in shares of Teva Pharm Adr by 20.5% in the third quarter. Chemical Bank now owns 32,579 shares of the company’s stock worth $1,499,000 after buying an additional 5,547 shares in the last quarter. Finally, Modera Wealth Management LLC boosted its stake in shares of Teva Pharm Adr by 9.5% in the third quarter. Modera Wealth Management LLC now owns 11,223 shares of the company’s stock worth $516,000 after buying an additional 975 shares in the last quarter. 54.53% of the stock is currently owned by institutional investors and hedge funds.
Shares of Teva Pharm Adr (NYSE:TEVA) traded down 1.85% during trading on Thursday, hitting $33.47. 7,498,760 shares of the stock were exchanged. The firm’s 50 day moving average price is $36.11 and its 200-day moving average price is $45.20. The stock has a market cap of $33.97 billion, a P/E ratio of 19.47 and a beta of 0.65. Teva Pharm Adr has a 52 week low of $33.46 and a 52 week high of $64.31.
Teva Pharm Adr (NYSE:TEVA) last posted its earnings results on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.02. The firm earned $5.56 billion during the quarter, compared to the consensus estimate of $5.71 billion. Teva Pharm Adr had a return on equity of 16.75% and a net margin of 8.81%. The company’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.35 EPS. On average, analysts predict that Teva Pharm Adr will post $5.12 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, December 20th. Investors of record on Monday, December 5th were given a $0.34 dividend. The ex-dividend date of this dividend was Thursday, December 1st. This represents a $1.36 dividend on an annualized basis and a yield of 4.06%. Teva Pharm Adr’s dividend payout ratio is presently 67.44%.
A number of equities research analysts recently issued reports on the stock. Deutsche Bank AG set a $68.00 price objective on shares of Teva Pharm Adr and gave the stock a “buy” rating in a report on Saturday, October 15th. Jefferies Group cut shares of Teva Pharm Adr from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $69.00 to $40.00 in a report on Sunday, December 4th. Morgan Stanley cut shares of Teva Pharm Adr from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $63.00 to $42.00 in a report on Sunday, December 4th. Oppenheimer Holdings Inc. reiterated an “outperform” rating on shares of Teva Pharm Adr in a report on Wednesday, December 7th. Finally, Bank of America Corp. cut shares of Teva Pharm Adr from a “buy” rating to a “neutral” rating and set a $48.00 price objective for the company. in a report on Monday, November 7th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $56.38.
Teva Pharm Adr Company Profile
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharm Adr (NYSE:TEVA).